148 related articles for article (PubMed ID: 19877883)
61. Guidelines for 131I-ethiodised oil (Lipiodol) therapy.
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP20-2. PubMed ID: 12723561
[No Abstract] [Full Text] [Related]
62. [Histopathological changes in rat transplanted hepatoma after lipiodol transarterial embolization].
Jiang B; Lou Q; Ding XF; Sa XY; Chen LR; Yu SY; Chao M
Zhonghua Zhong Liu Za Zhi; 2004 Apr; 26(4):205-8. PubMed ID: 15312380
[TBL] [Abstract][Full Text] [Related]
63. [Efficacy of 188Re-herceptin radioimmunotherapy in nude mouse model of nasopharyngeal carcinoma].
Li GP; Huang K; Zhang H
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Apr; 26(4):459-62. PubMed ID: 16624752
[TBL] [Abstract][Full Text] [Related]
64. Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol.
Zanzonico PB; Divgi C
Semin Nucl Med; 2008 Mar; 38(2):S30-9. PubMed ID: 18243841
[TBL] [Abstract][Full Text] [Related]
65. Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats.
Molina-Trinidad EM; de Murphy CA; Jung-Cook H; Stack EM; Pedraza-Lopez M; Morales-Marquez JL; Serrano GV
J Pharm Pharmacol; 2010 Apr; 62(4):456-61. PubMed ID: 20604834
[TBL] [Abstract][Full Text] [Related]
66. Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases.
Bretagne JF; Raoul JL; Bourguet P; Duvauferrier R; Deugnier Y; Faroux R; Ramée A; Herry JY; Gastard J
Radiology; 1988 Aug; 168(2):547-50. PubMed ID: 2839867
[TBL] [Abstract][Full Text] [Related]
67. [Effect of percutaneous intratumoral injection of lipiodol emulsion of chemotherapie agents on implanted VX2 tumor in rabbits].
Song JW; Li YH; Chen Y; Yang Y; Liu XH; Ning JJ; Yang J; Shi XX
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov; 30(11):2526-9. PubMed ID: 21097424
[TBL] [Abstract][Full Text] [Related]
68. Evaluation of three rhenium-188 candidates for intravascular radiation therapy with liquid-filled balloons to prevent restenosis.
Lin WY; Tsai SC; Hsieh BT; Lee TW; Ting G; Wang SJ
J Nucl Cardiol; 2000; 7(1):37-42. PubMed ID: 10698233
[TBL] [Abstract][Full Text] [Related]
69. Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals.
Ferro-Flores G; Arteaga de Murphy C
Adv Drug Deliv Rev; 2008 Sep; 60(12):1389-401. PubMed ID: 18547675
[TBL] [Abstract][Full Text] [Related]
70. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial.
Kumar A; Srivastava DN; Chau TT; Long HD; Bal C; Chandra P; Chien le T; Hoa NV; Thulkar S; Sharma S; Tam le H; Xuan TQ; Canh NX; Pant GS; Bandopadhyaya GP
Radiology; 2007 May; 243(2):509-19. PubMed ID: 17456873
[TBL] [Abstract][Full Text] [Related]
71. Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer.
Das T; Chakraborty S; Sarma HD; Venkatesh M; Banerjee S
Nucl Med Commun; 2009 May; 30(5):362-7. PubMed ID: 19282794
[TBL] [Abstract][Full Text] [Related]
72. [Interventional therapy combining Seed of Job's-stears with lipiodol for hepatoma-bearing rats].
Huang T; Wu W; Li Y; Zhang J; Huang L
Zhonghua Gan Zang Bing Za Zhi; 2002 Dec; 10(6):452-4. PubMed ID: 12502451
[TBL] [Abstract][Full Text] [Related]
73. Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol.
Banka VK; Moon SH; Jeong JM; Seelam SR; Lee YS; Kim YJ; Lee DS; Chung JK
Nucl Med Biol; 2015 Mar; 42(3):317-22. PubMed ID: 25537725
[TBL] [Abstract][Full Text] [Related]
74. Treatment of unresectable hepatocellular carcinoma with radiolabelled lipiodol.
Kanhere HA; Leopardi LN; Fischer L; Kitchener MI; Maddern GJ
ANZ J Surg; 2008 May; 78(5):371-6. PubMed ID: 18380736
[TBL] [Abstract][Full Text] [Related]
75. Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis.
Tabone M; Vigano' L; Ferrero A; Pellerito R; Carbonatto P; Capussotti L
Eur J Surg Oncol; 2007 Feb; 33(1):61-6. PubMed ID: 17175128
[TBL] [Abstract][Full Text] [Related]
76. Iodine-131-Lipiodol for hepatocellular carcinoma: the benefits of targeting.
Novell JR; Hilson AJ
J Nucl Med; 1994 Aug; 35(8):1318-20. PubMed ID: 8046486
[No Abstract] [Full Text] [Related]
77. [Selective internal radiotherapy (radioembolization) and radiation therapy for HCC--current status and perspectives].
Hilgard P; Müller S; Hamami M; Sauerwein WS; Haberkorn U; Gerken G; Antoch G
Z Gastroenterol; 2009 Jan; 47(1):37-54. PubMed ID: 19156591
[TBL] [Abstract][Full Text] [Related]
78. Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary?
Bacher K; Brans B; Monsieurs M; De Winter F; Dierckx RA; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1311-6. PubMed ID: 12271412
[TBL] [Abstract][Full Text] [Related]
79. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
Liepe K; Brogsitter C; Leonhard J; Wunderlich G; Hliscs R; Pinkert J; Folprecht G; Kotzerke J
Jpn J Clin Oncol; 2007 Dec; 37(12):942-50. PubMed ID: 18094017
[TBL] [Abstract][Full Text] [Related]
80. 188rhenium-TDD-lipiodol in treatment of inoperable primary hepatocellular carcinoma--a case report.
Sundram FX; Yu SW; Jeong JM; Somanesan S; Premaraj J; Saw MM; Tan BS
Ann Acad Med Singap; 2001 Sep; 30(5):542-5. PubMed ID: 11603144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
